Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront

Immunome Inc.

Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.
Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.
Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.
Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.
Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immunome Inc. entered into Collaboration Agreement with AbbVie Global Enterprises Ltd. valued at $30 million (effective 2023-01-04).

Action: entry
Agreement: collaboration
Counterparty: AbbVie Global Enterprises Ltd.
Value: $30 million
Effective: 2023-01-04

Exact text from the filing

On January 4, 2023, Immunome, Inc. (the “ Company ”) entered into a collaboration and option agreement (“ Collaboration Agreement ”) with AbbVie Global Enterprises Ltd. (“ AbbVie ”),

View on SEC.gov

154 material agreements filed in the last 30 days. Browse all material agreements →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-001705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.